(5E,7E,9E)-N,N-tetramethylene-4,11-dihydroxy-13-(p-methoxyphenyl)-trideca-5,7,9-trienamide | 104227-11-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: (5E,7E,9E)-N,N-tetramethylene-4,11-dihydroxy-13-(p-methoxyphenyl)-trideca-5,7,9-trienamide
• 英文别名: (5E,7E,9E)-4,11-dihydroxy-13-(4-methoxyphenyl)-1-pyrrolidin-1-yltrideca-5,7,9-trien-1-one
• CAS: 104227-11-4
• 化学式: C₂₄H₃₃NO₄
• 分子量: 399.53
• InChiKey: YLFGZUCQMWBMAT-GHXJCVKJSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  29
• 可旋转键数：
  11
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.46
• 拓扑面积：
  70
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为产物：
  描述：

  4-甲氧基苯丙酰氯 在 sodium tetrahydroborate 、 三氯化铝 作用下， 以 甲醇 为溶剂， 反应 4.5h， 生成 (5E,7E,9E)-N,N-tetramethylene-4,11-dihydroxy-13-(p-methoxyphenyl)-trideca-5,7,9-trienamide
  参考文献：
  名称：

  直接获得潜在的 LTB4-拮抗剂，SM-9064，通过，二甲硅烷基衍生物

  摘要：

  摘要 SM-9064 是一种潜在的 LTB4 拮抗剂，对某些类型的炎症有效，通过 (1E,3E,5E)-1,6-双(三甲基甲硅烷基)-1,3,5-己三烯和酰氯在三氯化铝存在下进行还原反应并形成吡咯烷衍生物。

  DOI：

  10.1080/00397919308009765

文献信息

• Soft tissue implants and anti-scarring agents
  申请人：Hunter L. William

  公开号：US20050142162A1

  公开（公告）日：2005-06-30

  Soft tissue implants (e.g., breast, pectoral, chin, facial, lip, and nasal implants) are used in combination with an anti-scarring agent in order to inhibit scarring that may otherwise occur when the implant is placed within an animal.

  软组织植入物（例如乳房、胸肌、下巴、面部、唇部和鼻部植入物）与抗瘢痕剂结合使用，以抑制动物体内植入物放置时可能发生的瘢痕形成。
• Unsaturated fatty acid derivatives and their production
  申请人：SUMITOMO PHARMACEUTICALS COMPANY, LIMITED

  公开号：EP0183177A1

  公开（公告）日：1986-06-04

  A compound of the formula: wherein Y is a free or esterified carboxyl group, or a group of the formula: (wherein Ra and Rb are each independently a hydrogen atom, a C1-C4 alkyl group, a C3-C7 cycloalkyl group, a benzyl group, a phenyl group, a phenyl group substituted with a halogen atom or a C1-C4 alkyl group, or, when taken together with the adjacent nitrogen atom, they represent a 5 to 7 membered saturated heterocyclic goup); R' is a C1-C12 alkyl group, a C2-C12 alkenyl group, a C2-C12 alkynyl group, a C3-C10 cycloalkyl group, a C4-C10 cycloalkenyl group, a hydroxy C1-C13 alkyl group, an C1-C12 alkyl group substituted with a group of the formula: (wherein Rc and Rd are each independently a hydrogen atom, or a C,-C4 alkyl group), a C3-C10 heterocyclic group, a phenyl group optionally substituted with one to three substituents selected from the group consisting of halogen atom, hydroxyl group, C1-C4 alkyl group, trifluoromethyl group, C1-C4 alkoxy group, and group of the formula: (wherein Rc and Rd are as defined above) or a group of the formula: [wherein A is a C1-C7 alkylene chain and B is a C3-C10 cycloalkyl group, a C4-C10 cycloalkenyl group, a C1-C12 alkoxy group, a C1-C12 alkylthio group, a C3-C10 cycloalkoxy group, a C4-C10 cycloalkenyloxy group, a C3-C10 heterocyclic group, or a phenyl or phenoxy group optionally substituted with one to three substituents selected from the group consisting of halogen atom, hydroxy group, C1-C4 alkyl group, group of the formula: (wherein Rc and Rd are as defined above), trifluoromethyl group, C1-C4 alkylthio group and C,-C4 alkoxy group]; n is 2, 3 or 4; R2 and R3 are hydrogen atoms or, when taken together, they mean a single linkage to form a trans double bond between the adjacent carbon atoms, and E is a cis or trans vinylene group; provided that when n is 3 and R' is a n-octyl group, a 2-octenyl group or a 2,5-octadienyl group, R2 and R3 are hydrogen atoms, and that when n is 2, E is a trans vinylene group or a non-toxic pharmaceutically acceptable salt thereof. Said compound have potent anti-leucotriene B4 action, and are useful in the treatment of inflammation and allergy.

  式中的化合物 其中 Y 是游离的或酯化的羧基，或者是式中的基团： (其中 Ra 和 Rb 各自独立地为氢原子、C1-C4 烷基、C3-C7 环烷基、苄基、苯基、被卤素原子或 C1-C4 烷基取代的苯基，或当与相邻的氮原子结合时，它们代表 5 至 7 个成员的饱和杂环基团）；R' 是 C1-C12 烷基、C2-C12 烯基、C2-C12 炔基、C3-C10 环烷基、C4-C10 环烯基、羟基 C1-C13 烷基、被式中基团取代的 C1-C12 烷基： (其中 Rc 和 Rd 各自独立地为氢原子或 C,-C4烷基）、C3-C10 杂环基团、任选被一至三个取代基取代的苯基，这些取代基可选自卤素原子、羟基、C1-C4 烷基、三氟甲基、C1-C4 烷氧基和式中的基团： (其中 Rc 和 Rd 如上定义）或式中的基团： [其中 A 为 C1-C7 亚烷基链，B 为 C3-C10 环烷基、C4-C10 环烯基、C1-C12 烷氧基、C1-C12 硫代烷基、C3-C10 环烷氧基、C4-C10 环烯氧基、C3-C10 杂环基，或任选被 1 至 3 个取代基取代的苯基或苯氧基，取代基可选自卤素原子、羟基、C1-C4 烷基、式中的基团： (其中 Rc 和 Rd 如上定义）、三氟甲基、C1-C4 烷硫基和 C,-C4 烷氧基]；n 为 2、3 或 4；R2 和 R3 为氢原子，或当它们结合在一起时，表示在相邻碳原子之间形成反式双键的单链，且 E 为顺式或反式亚乙烯基；当 n 为 3，R'为正辛基、2-辛烯基或 2,5-辛二烯基时，R2 和 R3 为氢原子；当 n 为 2 时，E 为反式乙烯基或其无毒性的药学上可接受的盐。上述化合物具有强效的抗白三烯 B4 作用，可用于治疗炎症和过敏。
• Electrical devices and anti-scarring agents
  申请人：Hunter L. William

  公开号：US20050182469A1

  公开（公告）日：2005-08-18

  Electrical devices (e.g., cardiac rhythm management and neurostimulation devices) for contact with tissue are used in combination with an anti-scarring agent (e.g., a cell cycle inhibitor) in order to inhibit scarring that may otherwise occur when the devices are implanted within an animal.

  用于与组织接触的电气设备（如心律管理和神经刺激设备）与抗疤痕剂（如细胞周期抑制剂）结合使用，以抑制设备植入动物体内时可能产生的疤痕。
• Polymer compositions and methods for their use
  申请人：Hunter L. William

  公开号：US20050183731A1

  公开（公告）日：2005-08-25

  Compositions comprising anti-fibrotic agent(s) and/or polymeric compositions can be used in various medical applications including the prevention of surgical adhesions, treatment of inflammatory arthritis, treatment of scars and keloids, the treatment of vascular disease, and the prevention of cartilage loss.

  包含抗纤维化剂和/或聚合物的组合物可用于各种医疗应用，包括预防手术粘连、治疗炎症性关节炎、治疗疤痕和瘢痕疙瘩、治疗血管疾病以及预防软骨流失。
• Drug delivery from rapid gelling polymer composition
  申请人：Angiotech International AG

  公开号：US20040225077A1

  公开（公告）日：2004-11-11

  Compositions are disclosed that afford drug delivery from two-part polymer compositions that rapidly form covalent linkages when mixed together. Such compositions are particularly well suited for use in a variety of tissue related applications when rapid adhesion to the tissue and gel formation is desired along with drug delivery. For example, the compositions are useful as tissue sealants, in promoting hemostasis, in effecting tissue adhesion, in providing tissue augmentation, and in the prevention of surgical adhesions.